This Company Wants to Rewrite the Future of Genetic Disease—Without Crispr Gene Editing
by Megan Molteni from Feed: All Latest on (#55FKS)
Tessera Therapeutics is developing a new class of gene editors capable of precisely plugging in long stretches of DNA-something that Crispr can't do.